According to the calculated tumor population rate, which was determined using the VAF and the copy number (CN)-status for KRAS, the cohort was divided into nine patients with clonal KRAS-mutations and seven patients with subclonal KRAS-mutations at diagnosis (Figure S1). This evidence concerns the gene KRAS and neoplasm.